|
Real-time Estimate
Tradegate
08:52:41 20/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 79.00 EUR | -0.13% |
|
-1.13% | +24.12% |
| 08-10 | Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial | MT |
| 08-10 | Orion partner's phase 3 study with levosimendan missed its goals | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 12.99B | |||||
| 1,141B | |||||
| 659B | - | - | - | ||
| 470B | |||||
| 366B | |||||
| 302B |
- Stock Market
- Stocks
- ORNBV Stock
- Charts Orion Oyj
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
